{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:46:29Z","timestamp":1793515589692,"version":"4.5.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Breakthrough T1D"},{"name":"Helmholtz Zentrum M\u00fcnchen - Deutsches Forschungszentrum f\u00fcr Gesundheit und Umwelt (GmbH)","id":[{"id":"https:\/\/ror.org\/00cfam450","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00125-026-06841-z","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:13:47Z","timestamp":1789049627000},"page":"3370-3395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes: a nominal group technique process"],"prefix":"10.1007","volume":"69","author":[{"given":"Anette-Gabriele","family":"Ziegler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian J.","family":"Rewers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Achenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstine J.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"DiMeglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjoy","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Elding Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte I.","family":"Frohnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt J.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Hagopian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Oron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitrin W.","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darja","family":"\u0160migoc Schweiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"\u0160umn\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Szypowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Veijola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Vercauteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Wentworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane K.","family":"Wherrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Albanese-O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"6841_CR1","doi-asserted-by":"publisher","first-page":"112277","DOI":"10.1016\/j.diabres.2025.112277","volume":"225","author":"GD Ogle","year":"2025","unstructured":"Ogle GD, Wang F, Haynes A et al (2025) Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: results from the International Diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Res Clin Pr 225:112277. https:\/\/doi.org\/10.1016\/j.diabres.2025.112277","journal-title":"Diabetes Res Clin Pr"},{"issue":"5","key":"6841_CR2","doi-asserted-by":"publisher","first-page":"e13562","DOI":"10.1111\/1753-0407.13562","volume":"16","author":"N Kandemir","year":"2024","unstructured":"Kandemir N, Vuralli D, Ozon A et al (2024) Epidemiology of type 1 diabetes mellitus in children and adolescents: a 50-year, single-center experience. J Diabetes 16(5):e13562. https:\/\/doi.org\/10.1111\/1753-0407.13562","journal-title":"J Diabetes"},{"issue":"10","key":"6841_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s001250100635","volume":"44","author":"FJ Service","year":"2001","unstructured":"Service FJ, O\u2019Brien PC (2001) The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 44(10):1215\u20131220. https:\/\/doi.org\/10.1007\/s001250100635","journal-title":"Diabetologia"},{"issue":"14","key":"6841_CR4","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/s0002-9149(99)80683-3","volume":"75","author":"The Diabetes Control and Complications Trial (DCCT) Research Group","year":"1995","unstructured":"The Diabetes Control and Complications Trial (DCCT) Research Group (1995) Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 75(14):894\u2013903. https:\/\/doi.org\/10.1016\/s0002-9149(99)80683-3","journal-title":"Am J Cardiol"},{"issue":"10","key":"6841_CR5","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"RA Insel","year":"2015","unstructured":"Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the American Diabetes Association. Diabetes Care 38(10):1964\u20131974. https:\/\/doi.org\/10.2337\/dc15-1419","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"6841_CR6","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-s002","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) 2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142025. Diabetes Care 48(Supplement_1):S27\u2013S49. https:\/\/doi.org\/10.2337\/dc25-s002","journal-title":"Diabetes Care"},{"issue":"4","key":"6841_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/bf00401207","volume":"35","author":"S Genovese","year":"1992","unstructured":"Genovese S, Bonifacio E, McNally JM et al (1992) Distinct cytoplasmic islet cell antibodies with different risks for type 1 (insulin-dependent) diabetes mellitus. Diabetologia 35(4):385\u2013388. https:\/\/doi.org\/10.1007\/bf00401207","journal-title":"Diabetologia"},{"issue":"7","key":"6841_CR8","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s001250050358","volume":"38","author":"E Bonifacio","year":"1995","unstructured":"Bonifacio E, Genovese S, Braghi S et al (1995) Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 38(7):816\u2013822. https:\/\/doi.org\/10.1007\/s001250050358","journal-title":"Diabetologia"},{"issue":"1","key":"6841_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/adc.85.1.16","volume":"85","author":"JA Edge","year":"2001","unstructured":"Edge JA, Hawkins MM, Winter DL, Dunger DB, GREENE S (2001) The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. Arch Dis Child 85(1):16. https:\/\/doi.org\/10.1136\/adc.85.1.16","journal-title":"Arch Dis Child"},{"issue":"5","key":"6841_CR10","doi-asserted-by":"publisher","first-page":"e170020","DOI":"10.1001\/jamapediatrics.2017.0020","volume":"171","author":"BE Hursh","year":"2017","unstructured":"Hursh BE, Ronsley R, Islam N, Mammen C, Panagiotopoulos C (2017) Acute kidney injury in children with type 1 diabetes hospitalized for diabetic ketoacidosis. JAMA Pediatr 171(5):e170020\u2013e170020. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.0020","journal-title":"JAMA Pediatr"},{"issue":"7","key":"6841_CR11","doi-asserted-by":"publisher","first-page":"e2720","DOI":"10.1210\/clinem\/dgab090","volume":"106","author":"P Marzuillo","year":"2021","unstructured":"Marzuillo P, Iafusco D, Zanfardino A et al (2021) Acute kidney injury and renal tubular damage in children with type 1 diabetes mellitus onset. J Clin Endocrinol Metab 106(7):e2720\u2013e2737. https:\/\/doi.org\/10.1210\/clinem\/dgab090","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"6841_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00125-013-2850-z","volume":"56","author":"S Fredheim","year":"2013","unstructured":"Fredheim S, Johannesen J, Johansen A et al (2013) Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels. Diabetologia 56(5):995\u20131003. https:\/\/doi.org\/10.1007\/s00125-013-2850-z","journal-title":"Diabetologia"},{"issue":"4","key":"6841_CR13","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s11845-023-03345-2","volume":"192","author":"L Kelly","year":"2023","unstructured":"Kelly L, Tuthill A (2023) Does diabetic ketoacidosis at diagnosis of type 1 diabetes mellitus predict poorer long-term glycemic control. Ir J M\u00e9d Sci 192(4):1703\u20131709. https:\/\/doi.org\/10.1007\/s11845-023-03345-2","journal-title":"Ir J M\u00e9d Sci"},{"issue":"4","key":"6841_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/pedi.13327","volume":"23","author":"H Clapin","year":"2022","unstructured":"Clapin H, Smith G, Vijayanand S, Jones T, Davis E, Haynes A (2022) Moderate and severe diabetic ketoacidosis at type 1 diabetes onset in children over two decades: a population-based study of prevalence and long-term glycemic outcomes. Pediatr Diabetes 23(4):473\u2013479. https:\/\/doi.org\/10.1111\/pedi.13327","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"6841_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/pedi.13185","volume":"22","author":"J Hammersen","year":"2021","unstructured":"Hammersen J, Tittel SR, Warncke K et al (2021) Previous diabetic ketoacidosis as a risk factor for recurrence in a large prospective contemporary pediatric cohort: results from the DPV initiative. Pediatr Diabetes 22(3):455\u2013462. https:\/\/doi.org\/10.1111\/pedi.13185","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"6841_CR16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2337\/dc20-1829","volume":"44","author":"B Karges","year":"2020","unstructured":"Karges B, Prinz N, Placzek K et al (2020) A comparison of familial and sporadic type 1 diabetes among young patients. Diabetes Care 44(5):1116\u20131124. https:\/\/doi.org\/10.2337\/dc20-1829","journal-title":"Diabetes Care"},{"issue":"3","key":"6841_CR17","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1002\/edm2.412","volume":"6","author":"S Ghetti","year":"2023","unstructured":"Ghetti S, Kuppermann N, Rewers A et al (2023) Cognitive function following diabetic ketoacidosis in young children with type 1 diabetes. Endocrinol Diabetes Metab 6(3):e412. https:\/\/doi.org\/10.1002\/edm2.412","journal-title":"Endocrinol Diabetes Metab"},{"issue":"3","key":"6841_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2337\/dc18-1405","volume":"42","author":"T Aye","year":"2019","unstructured":"Aye T, Mazaika PK, Mauras N et al (2019) Impact of early diabetic ketoacidosis on the developing brain. Diabetes Care 42(3):443\u2013449. https:\/\/doi.org\/10.2337\/dc18-1405","journal-title":"Diabetes Care"},{"issue":"8","key":"6841_CR19","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s00125-020-05152-1","volume":"63","author":"V Cherubini","year":"2020","unstructured":"Cherubini V, Grimsmann JM, \u00c5kesson K et al (2020) Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia 63(8):1530\u20131541. https:\/\/doi.org\/10.1007\/s00125-020-05152-1","journal-title":"Diabetologia"},{"issue":"Suppl 3","key":"6841_CR20","doi-asserted-by":"publisher","first-page":"B75","DOI":"10.1007\/pl00002958","volume":"44","author":"C L\u00e9vy-Marchal","year":"2001","unstructured":"L\u00e9vy-Marchal C, Patterson CC, Green A, EURODIAB ACE Study Group (2001) Geographical variation of presentation at diagnosis of type I diabetes in children: the EURODIAB Study. Diabetologia 44(Suppl 3):B75\u2013B80. https:\/\/doi.org\/10.1007\/pl00002958","journal-title":"Diabetologia"},{"key":"6841_CR21","doi-asserted-by":"publisher","first-page":"d4092","DOI":"10.1136\/bmj.d4092","volume":"343","author":"JA Usher-Smith","year":"2011","unstructured":"Usher-Smith JA, Thompson MJ, Sharp SJ, Walter FM (2011) Factors associated with the presence of diabetic ketoacidosis at diagnosis of diabetes in children and young adults: a systematic review. BMJ 343:d4092. https:\/\/doi.org\/10.1136\/bmj.d4092","journal-title":"BMJ"},{"issue":"03","key":"6841_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1055\/s-0044-102090","volume":"50","author":"J Gro\u00dfe","year":"2018","unstructured":"Gro\u00dfe J, Hornstein H, Manuwald U, Kugler J, Glauche I, Rothe U (2018) Incidence of diabetic ketoacidosis of new-onset type 1 diabetes in children and adolescents in different countries correlates with Human Development Index (HDI): an updated systematic review, meta-analysis, and meta-regression. Horm Metab Res 50(03):209\u2013222. https:\/\/doi.org\/10.1055\/s-0044-102090","journal-title":"Horm Metab Res"},{"key":"6841_CR23","doi-asserted-by":"publisher","unstructured":"Alonso GT, Reinauer C, Williams GM et al (2026) Regional deprivation and diabetic ketoacidosis at type 1 diabetes diagnosis in children and adolescents: international comparison among 6 countries. Horm Res Paediatr 99(4):591\u2013598. https:\/\/doi.org\/10.1159\/000543139","DOI":"10.1159\/000543139"},{"key":"6841_CR24","doi-asserted-by":"publisher","unstructured":"Schneider J, Gemulla G, Kiess W, Berner R, Hommel A (2023) Presymptomatic type 1 diabetes and disease severity at onset. Diabetologia 66(12):2387\u20132388. https:\/\/doi.org\/10.1007\/s00125-023-05999-0","DOI":"10.1007\/s00125-023-05999-0"},{"issue":"1","key":"6841_CR25","doi-asserted-by":"publisher","first-page":"2550952","DOI":"10.1155\/pedi\/2550952","volume":"2025","author":"KJ Bell","year":"2025","unstructured":"Bell KJ, Lain SJ, Stevens L, Craig ME, Donaghue KC, Nassar N (2025) Eighteen\u2010year incidence, health outcomes and costs associated with diabetic ketoacidosis at diagnosis of type 1 diabetes in children in NSW, Australia. Pediatr Diabetes 2025(1):2550952. https:\/\/doi.org\/10.1155\/pedi\/2550952","journal-title":"Pediatr Diabetes"},{"issue":"7","key":"6841_CR26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.2337\/dc20-0389","volume":"44","author":"ET Jensen","year":"2021","unstructured":"Jensen ET, Stafford JM, Saydah S et al (2021) Increase in prevalence of diabetic ketoacidosis at diagnosis among youth with type 1 diabetes: the SEARCH for diabetes in youth study. Diabetes Care 44(7):1573\u20131578. https:\/\/doi.org\/10.2337\/dc20-0389","journal-title":"Diabetes Care"},{"issue":"1","key":"6841_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2337\/dc19-0428","volume":"43","author":"GT Alonso","year":"2019","unstructured":"Alonso GT, Coakley A, Pyle L, Manseau K, Thomas S, Rewers A (2019) Diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado children, 2010\u20132017. Diabetes Care 43(1):117\u2013121. https:\/\/doi.org\/10.2337\/dc19-0428","journal-title":"Diabetes Care"},{"issue":"15","key":"6841_CR28","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1001\/jama.2015.1414","volume":"313","author":"A Rewers","year":"2015","unstructured":"Rewers A, Dong F, Slover RH, Klingensmith GJ, Rewers M (2015) Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998\u20132012. JAMA 313(15):1570\u20131572. https:\/\/doi.org\/10.1001\/jama.2015.1414","journal-title":"JAMA"},{"issue":"7","key":"6841_CR29","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.2337\/dc09-2344","volume":"33","author":"A Hekkala","year":"2010","unstructured":"Hekkala A, Reunanen A, Koski M, Knip M, Veijola R, Register FPD (2010) Age-related differences in the frequency of ketoacidosis at diagnosis of type 1 diabetes in children and adolescents. Diabetes Care 33(7):1500\u20131502. https:\/\/doi.org\/10.2337\/dc09-2344","journal-title":"Diabetes Care"},{"key":"6841_CR30","doi-asserted-by":"publisher","unstructured":"Marcovecchio ML, Hendriks AEJ, Delfin C et al (2024) The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults. Diabetologia 67(6):995\u20131008. https:\/\/doi.org\/10.1007\/s00125-024-06124-5","DOI":"10.1007\/s00125-024-06124-5"},{"issue":"1","key":"6841_CR31","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1210\/clinem\/dgae158","volume":"110","author":"M Sooy","year":"2024","unstructured":"Sooy M, Pyle L, Alonso GT et al (2024) Lower prevalence of diabetic ketoacidosis at diagnosis in research participants monitored for hyperglycemia. J Clin Endocrinol Metab 110(1):e80\u2013e86. https:\/\/doi.org\/10.1210\/clinem\/dgae158","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6841_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1001\/jama.2019.21565","volume":"323","author":"A-G Ziegler","year":"2020","unstructured":"Ziegler A-G, Kick K, Bonifacio E et al (2020) Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA 323(4):339\u2013351. https:\/\/doi.org\/10.1001\/jama.2019.21565","journal-title":"JAMA"},{"issue":"9","key":"6841_CR33","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00125-023-05953-0","volume":"66","author":"S Hummel","year":"2023","unstructured":"Hummel S, Carl J, Friedl N et al (2023) Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia 66(9):1633\u20131642. https:\/\/doi.org\/10.1007\/s00125-023-05953-0","journal-title":"Diabetologia"},{"issue":"10","key":"6841_CR34","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1111\/dom.16611","volume":"27","author":"V Cherubini","year":"2025","unstructured":"Cherubini V, Scaramuzza AE, Agrimi U et al (2025) Initial observations on the frequency of diabetic ketoacidosis following pilot screening for type 1 diabetes in the general Italian population. Diabetes Obes Metab 27(10):6039\u20136043. https:\/\/doi.org\/10.1111\/dom.16611","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"6841_CR35","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.2337\/dc11-1026","volume":"34","author":"HE Larsson","year":"2011","unstructured":"Larsson HE, Vehik K, Bell R et al (2011) Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care 34(11):2347\u20132352. https:\/\/doi.org\/10.2337\/dc11-1026","journal-title":"Diabetes Care"},{"issue":"1","key":"6841_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/s2213-8587(22)00351-5","volume":"11","author":"JS Hirsch","year":"2022","unstructured":"Hirsch JS (2022) FDA approves teplizumab: a milestone in type 1 diabetes. Lancet Diabetes Endocrinol 11(1):18. https:\/\/doi.org\/10.1016\/s2213-8587(22)00351-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6841_CR37","unstructured":"MHRA (2025) MHRA approves teplizumab to delay progression of type 1 diabetes. https:\/\/www.gov.uk\/government\/news\/mhra-approves-teplizumab-to-delay-progression-of-type-1-diabetes. Accessed 14 Aug 2025"},{"key":"6841_CR38","unstructured":"European Medicines Agency (2026) Teizeild (teplizumab). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/teizeild#authorisation-details. Accessed 28 Mar 2026"},{"issue":"1","key":"6841_CR39","first-page":"1","volume":"6","author":"Canada\u2019s Drug Agency","year":"2026","unstructured":"Canada\u2019s Drug Agency (2026) Reimbursement recommendation: teplizumab (Tzield). Can J Health Technol 6(1):1\u201326","journal-title":"Can J Health Technol"},{"issue":"583","key":"6841_CR40","doi-asserted-by":"publisher","first-page":"eabc8980","DOI":"10.1126\/scitranslmed.abc8980","volume":"13","author":"EK Sims","year":"2021","unstructured":"Sims EK, Bundy BN, Stier K et al (2021) Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 13(583):eabc8980. https:\/\/doi.org\/10.1126\/scitranslmed.abc8980","journal-title":"Sci Transl Med"},{"issue":"7","key":"6841_CR41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/nejmoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold KC, Bundy BN, Long SA et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381(7):603\u2013613. https:\/\/doi.org\/10.1056\/nejmoa1902226","journal-title":"N Engl J Med"},{"key":"6841_CR42","doi-asserted-by":"publisher","unstructured":"Karakus KE, Chesshir L, Walker S et al (2026) Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes. Diabetologia 69(5):1164\u20131175. https:\/\/doi.org\/10.1007\/s00125-025-06646-6","DOI":"10.1007\/s00125-025-06646-6"},{"issue":"3","key":"6841_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2337\/dci25-0066","volume":"49","author":"C Mathieu","year":"2026","unstructured":"Mathieu C, Sims EK, Chatenoud L, James EA, Atkinson MA, Herold KC (2026) Toward disease-modifying therapies in type 1 diabetes: focus on teplizumab. Diabetes Care 49(3):365\u2013374. https:\/\/doi.org\/10.2337\/dci25-0066","journal-title":"Diabetes Care"},{"issue":"10511","key":"6841_CR44","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/s0140-6736(25)01438-2","volume":"406","author":"A Ziegler","year":"2025","unstructured":"Ziegler A, Cengiz E, Kay T (2025) The future of type 1 diabetes therapy. Lancet 406(10511):1520\u20131534. https:\/\/doi.org\/10.1016\/s0140-6736(25)01438-2","journal-title":"Lancet"},{"key":"6841_CR45","unstructured":"World Health Organization (2020) Screening programmes: a short guide. Increase effectiveness, maximize benefits and minimize harm. Copenhagen: WHO Regional Office for Europe. https:\/\/www.who.int\/europe\/publications\/i\/item\/9789289054782"},{"issue":"3","key":"6841_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2105\/ajph.62.3.337","volume":"62","author":"AHV de Ven","year":"1972","unstructured":"de Ven AHV, Delbecq AL (1972) The nominal group as a research instrument for exploratory health studies. Am J Public Health 62(3):337\u2013342. https:\/\/doi.org\/10.2105\/ajph.62.3.337","journal-title":"Am J Public Health"},{"issue":"10","key":"6841_CR47","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s001250051044","volume":"41","author":"The EURODIAB ACE Study Group and The EURODIAB ACE Substudy 2 Study Group","year":"1998","unstructured":"The EURODIAB ACE Study Group and The EURODIAB ACE Substudy 2 Study Group (1998) Familial risk of type I diabetes in European children. Diabetologia 41(10):1151\u20131156. https:\/\/doi.org\/10.1007\/s001250051044","journal-title":"Diabetologia"},{"issue":"10035","key":"6841_CR48","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/s0140-6736(16)30507-4","volume":"387","author":"M Rewers","year":"2016","unstructured":"Rewers M, Ludvigsson J (2016) Environmental risk factors for type 1 diabetes. Lancet 387(10035):2340\u20132348. https:\/\/doi.org\/10.1016\/s0140-6736(16)30507-4","journal-title":"Lancet"},{"issue":"5","key":"6841_CR49","doi-asserted-by":"publisher","first-page":"e011144","DOI":"10.1136\/bmjopen-2016-011144","volume":"6","author":"J Raab","year":"2016","unstructured":"Raab J, Haupt F, Scholz M et al (2016) Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open 6(5):e011144. https:\/\/doi.org\/10.1136\/bmjopen-2016-011144","journal-title":"BMJ Open"},{"key":"6841_CR50","unstructured":"Breakthrough T1D\u00a0(2026) Type 1 diabetes early detection. https:\/\/www.breakthrought1d.org\/early-detection\/. Accessed 1 Mar 2026"},{"key":"6841_CR51","doi-asserted-by":"publisher","unstructured":"Bonifacio E, Coelho R, Ewald DA et al (2025) The efficacy of islet autoantibody screening with or without genetic pre-screening strategies for the identification of presymptomatic type 1 diabetes. Diabetologia 68(6):1101\u20131107. https:\/\/doi.org\/10.1007\/s00125-025-06408-4","DOI":"10.1007\/s00125-025-06408-4"},{"key":"6841_CR52","doi-asserted-by":"publisher","unstructured":"Vercauteren J, EDENT1FI Consortium, Mathieu C et al (2025) Harmonising terminology for type 1 diabetes: the EDENT1FI lexicon initiative. Lancet Diabetes Endocrinol 13(11):905\u2013907. https:\/\/doi.org\/10.1016\/s2213-8587(25)00284-0","DOI":"10.1016\/s2213-8587(25)00284-0"},{"key":"6841_CR53","doi-asserted-by":"publisher","unstructured":"Chambers D, Baxter S, Bastounis A et al (2025) The acceptability of blood spot screening and genome sequencing in newborn screening: a systematic review examining evidence and frameworks. Heal Technol Assess March:1\u201353. https:\/\/doi.org\/10.3310\/rtpq2268","DOI":"10.3310\/rtpq2268"},{"issue":"3","key":"6841_CR54","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2337\/cd18-0088","volume":"37","author":"C Mu\u00f1oz","year":"2019","unstructured":"Mu\u00f1oz C, Floreen A, Garey C et al (2019) Misdiagnosis and diabetic ketoacidosis at diagnosis of type 1 diabetes: patient and caregiver perspectives. Clin Diabetes 37(3):276\u2013281. https:\/\/doi.org\/10.2337\/cd18-0088","journal-title":"Clin Diabetes"},{"issue":"11","key":"6841_CR55","doi-asserted-by":"publisher","first-page":"e009088","DOI":"10.1136\/bmjopen-2015-009088","volume":"5","author":"BM Shields","year":"2015","unstructured":"Shields BM, Peters JL, Cooper C et al (2015) Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open 5(11):e009088. https:\/\/doi.org\/10.1136\/bmjopen-2015-009088","journal-title":"BMJ Open"},{"issue":"12","key":"6841_CR56","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.2337\/dc19-0593","volume":"42","author":"EK Sims","year":"2019","unstructured":"Sims EK, Geyer S, Johnson SB et al (2019) Who is enrolling? The path to monitoring in type 1 diabetes TrialNet\u2019s pathway to prevention. Diabetes Care 42(12):2228\u20132236. https:\/\/doi.org\/10.2337\/dc19-0593","journal-title":"Diabetes Care"},{"issue":"6","key":"6841_CR57","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.2337\/dc15-2292","volume":"39","author":"P Xu","year":"2016","unstructured":"Xu P, Krischer JP, Type 1 Diabetes TrialNet Study Group (2016) Prognostic classification factors associated with development of multiple autoantibodies, dysglycemia, and type 1 diabetes\u2014a recursive partitioning analysis. Diabetes Care 39(6):1036\u20131044. https:\/\/doi.org\/10.2337\/dc15-2292","journal-title":"Diabetes Care"},{"issue":"2","key":"6841_CR58","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/pedi.12541","volume":"19","author":"AM Hekkala","year":"2018","unstructured":"Hekkala AM, Ilonen J, Toppari J, Knip M, Veijola R (2018) Ketoacidosis at diagnosis of type 1 diabetes: effect of prospective studies with newborn genetic screening and follow up of risk children. Pediatr Diabetes 19(2):314\u2013319. https:\/\/doi.org\/10.1111\/pedi.12541","journal-title":"Pediatr Diabetes"},{"issue":"7","key":"6841_CR59","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2337\/dc24-2886","volume":"48","author":"M Rewers","year":"2025","unstructured":"Rewers M, Agardh D, Johnson SB et al (2025) Unfolding the mystery of autoimmunity: The Environmental Determinants of Diabetes in the Young (TEDDY) study. Diabetes Care 48(7):1125\u20131135. https:\/\/doi.org\/10.2337\/dc24-2886","journal-title":"Diabetes Care"},{"issue":"1","key":"6841_CR60","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12916-019-1360-3","volume":"17","author":"VS Hoffmann","year":"2019","unstructured":"Hoffmann VS, Wei\u00df A, Winkler C et al (2019) Landmark models to define the age-adjusted risk of developing stage 1 type 1 diabetes across childhood and adolescence. BMC Med 17(1):125. https:\/\/doi.org\/10.1186\/s12916-019-1360-3","journal-title":"BMC Med"},{"issue":"3","key":"6841_CR61","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1006\/jaut.1996.0055","volume":"9","author":"M Rewers","year":"1996","unstructured":"Rewers M, Norris JM, Eisenbarth GS et al (1996) Beta-cell autoantibodies in infants and toddlers without IDDM relatives: Diabetes Autoimmunity Study in the Young (DAISY). J Autoimmun 9(3):405\u2013410. https:\/\/doi.org\/10.1006\/jaut.1996.0055","journal-title":"J Autoimmun"},{"issue":"8","key":"6841_CR62","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1210\/jc.2003-031887","volume":"89","author":"JM Barker","year":"2004","unstructured":"Barker JM, Barriga KJ, Yu L et al (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 89(8):3896\u20133902. https:\/\/doi.org\/10.1210\/jc.2003-031887","journal-title":"J Clin Endocrinol Metab"},{"key":"6841_CR63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/pedi.12325","volume":"17","author":"HE Larsson","year":"2016","unstructured":"Larsson HE (2016) A Swedish approach to the prevention of type 1 diabetes. Pediatr Diabetes 17:73\u201377. https:\/\/doi.org\/10.1111\/pedi.12325","journal-title":"Pediatr Diabetes"},{"key":"6841_CR64","doi-asserted-by":"publisher","first-page":"1386513","DOI":"10.3389\/fped.2024.1386513","volume":"12","author":"MN Scherman","year":"2024","unstructured":"Scherman MN, Lind A, Hamdan S et al (2024) Home capillary sampling and screening for type 1 diabetes, celiac disease, and autoimmune thyroid disease in a Swedish general pediatric population: the TRIAD study. Front Pediatr 12:1386513. https:\/\/doi.org\/10.3389\/fped.2024.1386513","journal-title":"Front Pediatr"},{"issue":"8","key":"6841_CR65","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/s2213-8587(22)00141-3","volume":"10","author":"M Ghalwash","year":"2022","unstructured":"Ghalwash M, Dunne JL, Lundgren M et al (2022) Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 10(8):589\u2013596. https:\/\/doi.org\/10.1016\/s2213-8587(22)00141-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"6841_CR66","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00125-022-05780-9","volume":"65","author":"A Weiss","year":"2022","unstructured":"Weiss A, Zapardiel-Gonzalo J, Voss F et al (2022) Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia 65(12):2121\u20132131. https:\/\/doi.org\/10.1007\/s00125-022-05780-9","journal-title":"Diabetologia"},{"issue":"7","key":"6841_CR67","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/dc19-2003","volume":"43","author":"RB McQueen","year":"2020","unstructured":"McQueen RB, Rasmussen CG, Waugh K et al (2020) Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado. Diabetes Care 43(7):1496\u20131503. https:\/\/doi.org\/10.2337\/dc19-2003","journal-title":"Diabetes Care"},{"key":"6841_CR68","unstructured":"Wilson JMG, Jungner G (1968) Principles and practice of screening for disease.\u00a0Public Health Paper 34. World Health Organization, Geneva. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/762f0d2f-4225-46df-b060-c39b37b9d76d\/content"},{"issue":"6","key":"6841_CR69","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/s2213-8587(24)00101-3","volume":"12","author":"E Bonifacio","year":"2024","unstructured":"Bonifacio E, Winkler C, Achenbach P, Ziegler A-G (2024) Effect of population-wide screening for presymptomatic early-stage type 1 diabetes on paediatric clinical care. Lancet Diabetes Endocrinol 12(6):376\u2013378. https:\/\/doi.org\/10.1016\/s2213-8587(24)00101-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6841_CR70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00125-018-4706-z","volume":"62","author":"M Lundgren","year":"2019","unstructured":"Lundgren M, Jonsdottir B, Larsson HE, DiPiS study group (2019) Effect of screening for type 1 diabetes on early metabolic control: the DiPiS study. Diabetologia 62(1):53\u201357. https:\/\/doi.org\/10.1007\/s00125-018-4706-z","journal-title":"Diabetologia"},{"issue":"9","key":"6841_CR71","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/dc17-0558","volume":"40","author":"LM Duca","year":"2017","unstructured":"Duca LM, Wang B, Rewers M, Rewers A (2017) Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care 40(9):1249\u20131255. https:\/\/doi.org\/10.2337\/dc17-0558","journal-title":"Diabetes Care"},{"issue":"4","key":"6841_CR72","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2337\/dc21-1648","volume":"45","author":"FM Karl","year":"2022","unstructured":"Karl FM, Winkler C, Ziegler A-G, Laxy M, Achenbach P (2022) Costs of public health screening of children for presymptomatic type 1 diabetes in Bavaria, Germany. Diabetes Care 45(4):837\u2013844. https:\/\/doi.org\/10.2337\/dc21-1648","journal-title":"Diabetes Care"},{"issue":"1","key":"6841_CR73","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12916-025-04225-5","volume":"23","author":"EL Templeman","year":"2025","unstructured":"Templeman EL, Ferrat LA, Parikh HM et al (2025) Development and recalibration of a multivariable type 1 diabetes prediction model for type 1 diabetes across multiple screening studies. BMC Med 23(1):433. https:\/\/doi.org\/10.1186\/s12916-025-04225-5","journal-title":"BMC Med"},{"issue":"8","key":"6841_CR74","doi-asserted-by":"publisher","first-page":"e70082","DOI":"10.1111\/dme.70082","volume":"42","author":"E Holmes-Truscott","year":"2025","unstructured":"Holmes-Truscott E, Litterbach E, S\u00f8holm U et al (2025) Experiences of diabetes stigma among adults with type 1 and type 2 diabetes: a multi-study, multi-country, secondary analysis. Diabet Med 42(8):e70082. https:\/\/doi.org\/10.1111\/dme.70082","journal-title":"Diabet Med"},{"issue":"1","key":"6841_CR75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s2213-8587(23)00347-9","volume":"12","author":"J Speight","year":"2024","unstructured":"Speight J, Holmes-Truscott E, Garza M et al (2024) Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations. Lancet Diabetes Endocrinol 12(1):61\u201382. https:\/\/doi.org\/10.1016\/s2213-8587(23)00347-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"6841_CR76","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/s2213-8587(23)00084-0","volume":"11","author":"J Speight","year":"2023","unstructured":"Speight J, Holmes-Truscott E (2023) Challenging diabetes stigma starts and ends with all of us. Lancet Diabetes Endocrinol 11(6):380\u2013382. https:\/\/doi.org\/10.1016\/s2213-8587(23)00084-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6841_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2024\/9927027","volume":"2024","author":"LM Quinn","year":"2024","unstructured":"Quinn LM, Narendran P, Bhavra K et al (2024) Developing a general population screening programme for paediatric type 1 diabetes: evidence from a qualitative study of the perspectives and attitudes of parents. Pediatr Diabetes 2024(1):1\u201310. https:\/\/doi.org\/10.1155\/2024\/9927027","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"6841_CR78","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10389-018-0981-x","volume":"27","author":"K Kick","year":"2019","unstructured":"Kick K, Hoffmann VS, Lange K et al (2019) Feasibility and organization of a population-based screening for pre-symptomatic type 1 diabetes in children \u2014 evaluation of the Fr1da study. J Public Health 27(5):553\u2013560. https:\/\/doi.org\/10.1007\/s10389-018-0981-x","journal-title":"J Public Health"},{"issue":"10","key":"6841_CR79","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s13300-024-01637-z","volume":"15","author":"CS Kelly","year":"2024","unstructured":"Kelly CS, Wolf WA, Cornelius EM, Peter ME, Chapman KS, Dunne JL (2024) Insights into knowledge and attitudes about autoantibody screening from people affected by type 1 diabetes: a brief report. Diabetes Ther 15(10):2249\u20132261. https:\/\/doi.org\/10.1007\/s13300-024-01637-z","journal-title":"Diabetes Ther"},{"key":"6841_CR80","doi-asserted-by":"publisher","first-page":"1506240","DOI":"10.3389\/fpubh.2025.1506240","volume":"13","author":"S Angiulli","year":"2025","unstructured":"Angiulli S, Merolla A, Borgonovo E et al (2025) Universal capillary screening for chronic autoimmune, metabolic and cardiovascular diseases: feasibility and acceptability of the UNISCREEN study. Front Public Health 13:1506240. https:\/\/doi.org\/10.3389\/fpubh.2025.1506240","journal-title":"Front Public Health"},{"issue":"3","key":"6841_CR81","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2337\/dc21-0422","volume":"45","author":"LM Jacobsen","year":"2022","unstructured":"Jacobsen LM, Vehik K, Veijola R et al (2022) Heterogeneity of DKA incidence and age-specific clinical characteristics in children diagnosed with type 1 diabetes in the TEDDY study. Diabetes Care 45(3):624\u2013633. https:\/\/doi.org\/10.2337\/dc21-0422","journal-title":"Diabetes Care"},{"issue":"1","key":"6841_CR82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/s2213-8587(24)00337-1","volume":"13","author":"S Hummel","year":"2025","unstructured":"Hummel S, Koeger M, Bonifacio E, Ziegler A-G (2025) Dysglycaemia definitions and progression to clinical type 1 diabetes in children with multiple islet autoantibodies. Lancet Diabetes Endocrinol 13(1):10\u201312. https:\/\/doi.org\/10.1016\/s2213-8587(24)00337-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"6841_CR83","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1001\/jama.2013.6285","volume":"309","author":"AG Ziegler","year":"2013","unstructured":"Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309(23):2473\u20132479. https:\/\/doi.org\/10.1001\/jama.2013.6285","journal-title":"JAMA"},{"issue":"3","key":"6841_CR84","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2337\/dc25-1021","volume":"49","author":"M Koeger","year":"2026","unstructured":"Koeger M, Winkler C, Hummel S et al (2026) Generalizability of progression risk in the TN-10 trial to a European population with or without a first-degree relative with type 1 diabetes. Diabetes Care 49(3):393\u2013400. https:\/\/doi.org\/10.2337\/dc25-1021","journal-title":"Diabetes Care"},{"issue":"7","key":"6841_CR85","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2337\/diab.40.7.831","volume":"40","author":"C Allen","year":"1991","unstructured":"Allen C, Palta M, D\u2019Alessio DJ (1991) Risk of diabetes in siblings and other relatives of IDDM subjects. Diabetes 40(7):831\u2013836. https:\/\/doi.org\/10.2337\/diab.40.7.831","journal-title":"Diabetes"},{"issue":"6","key":"6841_CR86","doi-asserted-by":"publisher","first-page":"100854","DOI":"10.1016\/j.xgen.2025.100854","volume":"5","author":"F Wang","year":"2025","unstructured":"Wang F, Liu A, Yang Z et al (2025) Effects of parental autoimmune diseases on type 1 diabetes in offspring can be partially explained by HLA and non-HLA polymorphisms. Cell Genom 5(6):100854. https:\/\/doi.org\/10.1016\/j.xgen.2025.100854","journal-title":"Cell Genom"},{"issue":"8","key":"6841_CR87","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1210\/jc.2003-032084","volume":"89","author":"AP Lambert","year":"2004","unstructured":"Lambert AP, Gillespie KM, Thomson G et al (2004) Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 89(8):4037\u20134043. https:\/\/doi.org\/10.1210\/jc.2003-032084","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6841_CR88","doi-asserted-by":"publisher","first-page":"e1002548","DOI":"10.1371\/journal.pmed.1002548","volume":"15","author":"E Bonifacio","year":"2018","unstructured":"Bonifacio E, Beyerlein A, Hippich M et al (2018) Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: a prospective study in children. PLoS Med 15(4):e1002548. https:\/\/doi.org\/10.1371\/journal.pmed.1002548","journal-title":"PLoS Med"},{"issue":"8","key":"6841_CR89","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1111\/dom.16454","volume":"27","author":"SV Edelman","year":"2025","unstructured":"Edelman SV, Agardh D, Cui N, Hao L, Wieloch M, Meneghini L (2025) Risk of new-onset type 1 diabetes in individuals with celiac disease and thyroid disease\u2014an observational study. Diabetes Obes Metab 27(8):4229\u20134238. https:\/\/doi.org\/10.1111\/dom.16454","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6841_CR90","doi-asserted-by":"publisher","first-page":"e22912","DOI":"10.7759\/cureus.22912","volume":"14","author":"GVF Monar","year":"2022","unstructured":"Monar GVF, Islam H, Puttagunta SM et al (2022) Association between type 1 diabetes mellitus and celiac disease: autoimmune disorders with a shared genetic background. Cureus 14(3):e22912. https:\/\/doi.org\/10.7759\/cureus.22912","journal-title":"Cureus"},{"key":"6841_CR91","doi-asserted-by":"publisher","first-page":"618213","DOI":"10.3389\/fendo.2021.618213","volume":"12","author":"L Frommer","year":"2021","unstructured":"Frommer L, Kahaly GJ (2021) Type 1 diabetes and autoimmune thyroid disease\u2014the genetic link. Front Endocrinol 12:618213. https:\/\/doi.org\/10.3389\/fendo.2021.618213","journal-title":"Front Endocrinol"},{"key":"6841_CR92","doi-asserted-by":"publisher","unstructured":"Wilson L, Hanna M, Gaind N, Pushkarna D, Breznen B (2025) 1509-P: association between autoimmune diseases and development of autoimmune type 1 diabetes (T1D)\u2014a targeted literature review (TLR). Diabetes 74(Supplement_1):1509-P. https:\/\/doi.org\/10.2337\/db25-1509-p","DOI":"10.2337\/db25-1509-p"},{"issue":"10391","key":"6841_CR93","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/s0140-6736(23)00457-9","volume":"401","author":"N Conrad","year":"2023","unstructured":"Conrad N, Misra S, Verbakel JY et al (2023) Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401(10391):1878\u20131890. https:\/\/doi.org\/10.1016\/s0140-6736(23)00457-9","journal-title":"Lancet"},{"issue":"11","key":"6841_CR94","doi-asserted-by":"publisher","first-page":"e15419","DOI":"10.1111\/dme.15419","volume":"41","author":"KJ Bell","year":"2024","unstructured":"Bell KJ, Brodie S, Couper JJ et al (2024) Protocol for the Australian Type 1 Diabetes National Screening Pilot: assessing the feasibility and acceptability of three general population screening models in children. Diabet Med 41(11):e15419. https:\/\/doi.org\/10.1111\/dme.15419","journal-title":"Diabet Med"},{"issue":"9","key":"6841_CR95","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00125-024-06205-5","volume":"67","author":"M Phillip","year":"2024","unstructured":"Phillip M, Achenbach P, Addala A et al (2024) Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia 67(9):1731\u20131759. https:\/\/doi.org\/10.1007\/s00125-024-06205-5","journal-title":"Diabetologia"},{"issue":"1","key":"6841_CR96","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/s2213-8587(23)00354-6","volume":"12","author":"E Bosi","year":"2024","unstructured":"Bosi E, Catassi C (2024) Screening type 1 diabetes and celiac disease by law. Lancet Diabetes Endocrinol 12(1):12\u201314. https:\/\/doi.org\/10.1016\/s2213-8587(23)00354-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"6841_CR97","doi-asserted-by":"publisher","first-page":"e0328624","DOI":"10.1371\/journal.pone.0328624","volume":"20","author":"O Vincentini","year":"2025","unstructured":"Vincentini O, Pricci F, Silano M et al (2025) Study protocol of D1Ce Screen: a pilot project of the Italian national screening program for type 1 diabetes and coeliac disease in the paediatric population. PLOS One 20(8):e0328624. https:\/\/doi.org\/10.1371\/journal.pone.0328624","journal-title":"PLOS One"},{"key":"6841_CR98","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ebiom.2019.08.036","volume":"47","author":"Y Gu","year":"2019","unstructured":"Gu Y, Zhao Z, Waugh K et al (2019) High-throughput multiplexed autoantibody detection to screen type 1 diabetes and multiple autoimmune diseases simultaneously. EBioMedicine 47:365\u2013372. https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.036","journal-title":"EBioMedicine"},{"key":"6841_CR99","doi-asserted-by":"publisher","first-page":"e63787","DOI":"10.3791\/63787","volume":"185","author":"X Jia","year":"2022","unstructured":"Jia X, He L, Miao D, Zhang C, Rewers M, Yu L (2022) A high-throughput multiplexed screening for type 1 diabetes, celiac diseases, and COVID-19. J Vis Exp 185:e63787. https:\/\/doi.org\/10.3791\/63787","journal-title":"J Vis Exp"},{"issue":"2","key":"6841_CR100","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2337\/dc21-0602","volume":"45","author":"AK Steck","year":"2021","unstructured":"Steck AK, Dong F, Rasmussen CG et al (2021) CGM metrics predict imminent progression to type 1 diabetes: Autoimmunity Screening for Kids (ASK) study. Diabetes Care 45(2):365\u2013371. https:\/\/doi.org\/10.2337\/dc21-0602","journal-title":"Diabetes Care"},{"issue":"1","key":"6841_CR101","doi-asserted-by":"publisher","first-page":"e088522","DOI":"10.1136\/bmjopen-2024-088522","volume":"15","author":"L Hoffmann","year":"2025","unstructured":"Hoffmann L, Kohls M, Arnolds S et al (2025) EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents. BMJ Open 15(1):e088522. https:\/\/doi.org\/10.1136\/bmjopen-2024-088522","journal-title":"BMJ Open"},{"issue":"4","key":"6841_CR102","doi-asserted-by":"publisher","first-page":"994","DOI":"10.2337\/dc21-1752","volume":"45","author":"JL Harding","year":"2022","unstructured":"Harding JL, Wander PL, Zhang X et al (2022) The incidence of adult-onset type 1 diabetes: a systematic review from 32 countries and regions. Diabetes Care 45(4):994\u20131006. https:\/\/doi.org\/10.2337\/dc21-1752","journal-title":"Diabetes Care"},{"issue":"8","key":"6841_CR103","doi-asserted-by":"publisher","first-page":"bvaf095","DOI":"10.1210\/jendso\/bvaf095","volume":"9","author":"ME Pauley","year":"2025","unstructured":"Pauley ME, Simmons KM, Dong F et al (2025) Prevalence of islet autoantibodies in adults without diabetes. J Endocr Soc 9(8):bvaf095. https:\/\/doi.org\/10.1210\/jendso\/bvaf095","journal-title":"J Endocr Soc"},{"issue":"7","key":"6841_CR104","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s001250051235","volume":"42","author":"E Bosi","year":"1999","unstructured":"Bosi E, Garancini MP, Poggiali F, Bonifacio E, Gallus G (1999) Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet autoantibodies in the general adult population of northern Italy. Diabetologia 42(7):840\u2013844. https:\/\/doi.org\/10.1007\/s001250051235","journal-title":"Diabetologia"},{"issue":"9","key":"6841_CR105","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2337\/dc25-0192","volume":"48","author":"EL Templeman","year":"2025","unstructured":"Templeman EL, Ferrat LA, Thomas N et al (2025) Contrasting adult and pediatric populations in a cohort of at-risk relatives in the T1D TrialNet pathway to prevention study. Diabetes Care 48(9):1571\u20131580. https:\/\/doi.org\/10.2337\/dc25-0192","journal-title":"Diabetes Care"},{"issue":"2","key":"6841_CR106","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.2337\/dc22-1673","volume":"46","author":"RG McCoy","year":"2022","unstructured":"McCoy RG, Herrin J, Galindo RJ et al (2022) Rates of hypoglycemic and hyperglycemic emergencies among U.S. adults with diabetes, 2011\u20132020. Diabetes Care 46(2):e69\u2013e71. https:\/\/doi.org\/10.2337\/dc22-1673","journal-title":"Diabetes Care"},{"key":"6841_CR107","unstructured":"T1DRA Study Group (n.d.) The Type 1 Diabetes Risk in Adults (T1DRA) study. https:\/\/t1dra.bristol.ac.uk\/. Accessed 5 Mar 2025"},{"issue":"5","key":"6841_CR108","doi-asserted-by":"publisher","first-page":"e15490","DOI":"10.1111\/dme.15490","volume":"42","author":"LM Quinn","year":"2025","unstructured":"Quinn LM, Dias RP, Greenfield SM et al (2025) Protocol for a feasibility and acceptability study for UK general population paediatric type 1 diabetes screening\u2014the EarLy Surveillance for Autoimmune diabetes (ELSA) study. Diabet Med 42(5):e15490. https:\/\/doi.org\/10.1111\/dme.15490","journal-title":"Diabet Med"},{"issue":"7","key":"6841_CR109","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00125-012-2472-x","volume":"55","author":"A-G Ziegler","year":"2012","unstructured":"Ziegler A-G, Bonifacio E, BABYDIAB-BABYDIET Study Group (2012) Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 55(7):1937\u20131943. https:\/\/doi.org\/10.1007\/s00125-012-2472-x","journal-title":"Diabetologia"},{"issue":"10","key":"6841_CR110","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.2337\/dc20-2122","volume":"44","author":"E Bonifacio","year":"2021","unstructured":"Bonifacio E, Wei\u00df A, Winkler C et al (2021) An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood. Diabetes Care 44(10):2260\u20132268. https:\/\/doi.org\/10.2337\/dc20-2122","journal-title":"Diabetes Care"},{"issue":"6","key":"6841_CR111","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/dom.16354","volume":"27","author":"E Bonifacio","year":"2025","unstructured":"Bonifacio E, Ziegler A (2025) Type 1 diabetes risk factors, risk prediction and presymptomatic detection: evidence and guidance for screening. Diabetes Obes Metab 27(6):28\u201339. https:\/\/doi.org\/10.1111\/dom.16354","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"6841_CR112","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/s2352-4642(22)00350-9","volume":"7","author":"M Ghalwash","year":"2023","unstructured":"Ghalwash M, Anand V, Lou O et al (2023) Islet autoantibody screening in at-risk adolescents to predict type 1 diabetes until young adulthood: a prospective cohort study. Lancet Child Adolesc Health 7(4):261\u2013268. https:\/\/doi.org\/10.1016\/s2352-4642(22)00350-9","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"6841_CR113","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00125-019-05047-w","volume":"63","author":"LM Jacobsen","year":"2020","unstructured":"Jacobsen LM, Bocchino L, Evans-Molina C et al (2020) The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia 63(3):588\u2013596. https:\/\/doi.org\/10.1007\/s00125-019-05047-w","journal-title":"Diabetologia"},{"issue":"8","key":"6841_CR114","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1210\/jc.2017-00569","volume":"102","author":"E Bosi","year":"2017","unstructured":"Bosi E, Boulware DC, Becker DJ et al (2017) Impact of age and antibody type on progression from single to multiple autoantibodies in type 1 diabetes relatives. J Clin Endocrinol Metab 102(8):2881\u20132886. https:\/\/doi.org\/10.1210\/jc.2017-00569","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"6841_CR115","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1089\/dia.2016.0199","volume":"18","author":"A-G Ziegler","year":"2016","unstructured":"Ziegler A-G, Haupt F, Scholz M et al (2016) 3 screen ELISA for high-throughput detection of beta cell autoantibodies in capillary blood. Diabetes Technol Ther 18(11):687\u2013693. https:\/\/doi.org\/10.1089\/dia.2016.0199","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"6841_CR116","doi-asserted-by":"publisher","first-page":"180","DOI":"10.14309\/ajg.0000000000000751","volume":"116","author":"MG Stahl","year":"2020","unstructured":"Stahl MG, Rasmussen CG, Dong F et al (2020) Mass screening for celiac disease: the autoimmunity screening for kids study. Am J Gastroenterol 116(1):180\u2013187. https:\/\/doi.org\/10.14309\/ajg.0000000000000751","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"6841_CR117","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/s2213-8587(25)00029-4","volume":"13","author":"D Beran","year":"2025","unstructured":"Beran D, Bandini A, Bosi E et al (2025) Type 1 diabetes screening: need for ethical, equity, and health systems perspective. Lancet Diabetes Endocrinol 13(3):175\u2013176. https:\/\/doi.org\/10.1016\/s2213-8587(25)00029-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"6841_CR118","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/archdischild-2023-326697","volume":"109","author":"C Scudder","year":"2024","unstructured":"Scudder C, Townson J, Bowen-Morris J et al (2024) General population screening for type 1 diabetes using islet autoantibodies at the preschool vaccination visit: a proof-of-concept study (the T1Early study). Arch Dis Childh 109(10):812\u2013817. https:\/\/doi.org\/10.1136\/archdischild-2023-326697","journal-title":"Arch Dis Childh"},{"issue":"3","key":"6841_CR119","doi-asserted-by":"publisher","first-page":"e078983","DOI":"10.1136\/bmjopen-2023-078983","volume":"14","author":"A Merolla","year":"2024","unstructured":"Merolla A, Lorenzo RD, Ferrannini G et al (2024) Universal screening for early detection of chronic autoimmune, metabolic and cardiovascular diseases in the general population using capillary blood (UNISCREEN): low-risk interventional, single-centre, pilot study protocol. BMJ Open 14(3):e078983. https:\/\/doi.org\/10.1136\/bmjopen-2023-078983","journal-title":"BMJ Open"},{"issue":"5","key":"6841_CR120","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00125-023-05877-9","volume":"66","author":"I Marzinotto","year":"2023","unstructured":"Marzinotto I, Pittman DL, Williams AJK et al (2023) Islet Autoantibody Standardization Program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops. Diabetologia 66(5):897\u2013912. https:\/\/doi.org\/10.1007\/s00125-023-05877-9","journal-title":"Diabetologia"},{"issue":"12","key":"6841_CR121","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2337\/diabetes.47.12.1857","volume":"47","author":"CF Verge","year":"1998","unstructured":"Verge CF, Stenger D, Bonifacio E et al (1998) Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 47(12):1857\u20131866. https:\/\/doi.org\/10.2337\/diabetes.47.12.1857","journal-title":"Diabetes"},{"issue":"12","key":"6841_CR122","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1007\/s00125-002-0949-8","volume":"45","author":"K Decochez","year":"2002","unstructured":"Decochez K, Leeuw IHD, Keymeulen B et al (2002) IA-2 autoantibodies predict impending type I diabetes in siblings of patients. Diabetologia 45(12):1658\u20131666. https:\/\/doi.org\/10.1007\/s00125-002-0949-8","journal-title":"Diabetologia"},{"issue":"2","key":"6841_CR123","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/diabetes.53.2.384","volume":"53","author":"P Achenbach","year":"2004","unstructured":"Achenbach P, Warncke K, Reiter J et al (2004) Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 53(2):384\u2013392. https:\/\/doi.org\/10.2337\/diabetes.53.2.384","journal-title":"Diabetes"},{"issue":"5","key":"6841_CR124","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00125-025-06382-x","volume":"68","author":"EK Sims","year":"2025","unstructured":"Sims EK, Cuthbertson D, Ferrat LA et al (2025) IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes. Diabetologia 68(5):993\u20131004. https:\/\/doi.org\/10.1007\/s00125-025-06382-x","journal-title":"Diabetologia"},{"issue":"9","key":"6841_CR125","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2337\/dc16-0181","volume":"39","author":"K Vehik","year":"2016","unstructured":"Vehik K, Lynch KF, Schatz DA et al (2016) Reversion of \u03b2-cell autoimmunity changes risk of type 1 diabetes: TEDDY study. Diabetes Care 39(9):1535\u20131542. https:\/\/doi.org\/10.2337\/dc16-0181","journal-title":"Diabetes Care"},{"issue":"1","key":"6841_CR126","doi-asserted-by":"publisher","first-page":"4238394","DOI":"10.1155\/2024\/4238394","volume":"2024","author":"T Oron","year":"2024","unstructured":"Oron T, de Jesus Cortez F, Shtaif B et al (2024) Detection of islet autoantibodies in whole blood by Antibody Detection by Agglutination\u2010PCR (ADAP) technology is sensitive and suitable for general population screening programs. Pediatr Diabetes 2024(1):4238394. https:\/\/doi.org\/10.1155\/2024\/4238394","journal-title":"Pediatr Diabetes"},{"issue":"7","key":"6841_CR127","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/dme.13338","volume":"34","author":"Y Liu","year":"2017","unstructured":"Liu Y, Rafkin LE, Matheson D et al (2017) Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study. Diabet Med 34(7):934\u2013937. https:\/\/doi.org\/10.1111\/dme.13338","journal-title":"Diabet Med"},{"issue":"2","key":"6841_CR128","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1089\/dia.2023.0345","volume":"26","author":"ABE Sing","year":"2024","unstructured":"Sing ABE, Naselli G, Huang D et al (2024) Feasibility and validity of in-home self-collected capillary blood spot screening for type 1 diabetes risk. Diabetes Technol Ther 26(2):87\u201394. https:\/\/doi.org\/10.1089\/dia.2023.0345","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"6841_CR129","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc24-2443","volume":"48","author":"JM Wentworth","year":"2025","unstructured":"Wentworth JM, Sing ABE, Naselli G et al (2025) Islet autoantibody screening throughout Australia using in-home blood spot sampling: 2-year outcomes of Type1Screen. Diabetes Care 48(4):556\u2013563. https:\/\/doi.org\/10.2337\/dc24-2443","journal-title":"Diabetes Care"},{"issue":"5","key":"6841_CR130","doi-asserted-by":"publisher","first-page":"e004480","DOI":"10.1136\/bmjdrc-2024-004480","volume":"12","author":"LM Quinn","year":"2024","unstructured":"Quinn LM, Dias RP, Bidder C et al (2024) Presentation and characteristics of children with screen-detected type 1 diabetes: learnings from the ELSA general population pediatric screening study. BMJ Open Diabetes Res Care 12(5):e004480. https:\/\/doi.org\/10.1136\/bmjdrc-2024-004480","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"6841_CR131","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00125-025-06461-z","volume":"68","author":"S Martinenghi","year":"2025","unstructured":"Martinenghi S, Merolla A, Grogan P et al (2025) Prevention of diabetic ketoacidosis in relatives screened for islet autoantibodies and followed up in the TrialNet Pathway to Prevention study at a single institution in Italy. Diabetologia 68(9):1889\u20131898. https:\/\/doi.org\/10.1007\/s00125-025-06461-z","journal-title":"Diabetologia"},{"issue":"3","key":"6841_CR132","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s00125-015-3830-2","volume":"59","author":"PJ Bingley","year":"2016","unstructured":"Bingley PJ, Boulware DC, Krischer JP, Type 1 Diabetes TrialNet Study Group (2016) The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia 59(3):542\u2013549. https:\/\/doi.org\/10.1007\/s00125-015-3830-2","journal-title":"Diabetologia"},{"issue":"2","key":"6841_CR133","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00125-014-3443-1","volume":"58","author":"R Chmiel","year":"2015","unstructured":"Chmiel R, Giannopoulou EZ, Winkler C, Achenbach P, Ziegler A-G, Bonifacio E (2015) Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening. Diabetologia 58(2):411\u2013413. https:\/\/doi.org\/10.1007\/s00125-014-3443-1","journal-title":"Diabetologia"},{"issue":"5","key":"6841_CR134","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s11892-011-0208-9","volume":"11","author":"SB Johnson","year":"2011","unstructured":"Johnson SB (2011) Psychological impact of screening and prediction in type 1 diabetes. Curr Diabetes Rep 11(5):454\u2013459. https:\/\/doi.org\/10.1007\/s11892-011-0208-9","journal-title":"Curr Diabetes Rep"},{"issue":"5","key":"6841_CR135","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/pedi.13173","volume":"22","author":"LB Smith","year":"2021","unstructured":"Smith LB, Lynch KF, Driscoll KA, Johnson SB, TEDDY Study Group (2021) Parental monitoring for type 1 diabetes in genetically at-risk young children: the TEDDY study. Pediatr Diabetes 22(5):717\u2013728. https:\/\/doi.org\/10.1111\/pedi.13173","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"6841_CR136","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/pedi.12168","volume":"16","author":"R Roth","year":"2015","unstructured":"Roth R, Lynch K, Lernmark B et al (2015) Maternal anxiety about a child\u2019s diabetes risk in the TEDDY study: the potential role of life stress, postpartum depression, and risk perception. Pediatr Diabetes 16(4):287\u2013298. https:\/\/doi.org\/10.1111\/pedi.12168","journal-title":"Pediatr Diabetes"},{"issue":"12","key":"6841_CR137","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.2337\/dc23-0350","volume":"46","author":"HK O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell HK, Rasmussen CG, Dong F et al (2023) Anxiety and risk perception in parents of children identified by population screening as high risk for type 1 diabetes. Diabetes Care 46(12):2155\u20132161. https:\/\/doi.org\/10.2337\/dc23-0350","journal-title":"Diabetes Care"},{"issue":"12","key":"6841_CR138","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.2337\/dc21-0740","volume":"44","author":"A Dehn-Hindenberg","year":"2021","unstructured":"Dehn-Hindenberg A, Sa\u00dfmann H, Berndt V et al (2021) Long-term occupational consequences for families of children with type 1 diabetes: the mothers take the burden. Diabetes Care 44(12):2656\u20132663. https:\/\/doi.org\/10.2337\/dc21-0740","journal-title":"Diabetes Care"},{"issue":"4","key":"6841_CR139","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40273-025-01581-1","volume":"44","author":"G Leiria","year":"2026","unstructured":"Leiria G, McQueen RB, Jackson C et al (2026) Development of a patient-level multi-objective optimisation model for screening strategies for childhood type 1 diabetes. PharmacoEconomics 44(4):495\u2013507. https:\/\/doi.org\/10.1007\/s40273-025-01581-1","journal-title":"PharmacoEconomics"},{"issue":"8","key":"6841_CR140","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/pedi.12313","volume":"16","author":"C Meehan","year":"2015","unstructured":"Meehan C, Fout B, Ashcraft J, Schatz DA, Haller MJ (2015) Screening for T1D risk to reduce DKA is not economically viable. Pediatr Diabetes 16(8):565\u2013572. https:\/\/doi.org\/10.1111\/pedi.12313","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"6841_CR141","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00125-015-3514-y","volume":"58","author":"JP Krischer","year":"2015","unstructured":"Krischer JP, Lynch KF, Schatz DA et al (2015) The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 58(5):980\u2013987. https:\/\/doi.org\/10.1007\/s00125-015-3514-y","journal-title":"Diabetologia"},{"issue":"10","key":"6841_CR142","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.2337\/db13-0300","volume":"62","author":"J Ilonen","year":"2013","unstructured":"Ilonen J, Hammais A, Laine A-P et al (2013) Patterns of \u03b2-cell autoantibody appearance and genetic associations during the first years of life. Diabetes 62(10):3636\u20133640. https:\/\/doi.org\/10.2337\/db13-0300","journal-title":"Diabetes"},{"issue":"2","key":"6841_CR143","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/joim.13648","volume":"294","author":"\u00c5 Lernmark","year":"2023","unstructured":"Lernmark \u00c5, Akolkar B, Hagopian W et al (2023) Possible heterogeneity of initial pancreatic islet beta-cell autoimmunity heralding type 1 diabetes. J Intern Med 294(2):145\u2013158. https:\/\/doi.org\/10.1111\/joim.13648","journal-title":"J Intern Med"},{"key":"6841_CR144","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaut.2019.04.007","volume":"101","author":"JF Baizabal-Carvallo","year":"2019","unstructured":"Baizabal-Carvallo JF (2019) The neurological syndromes associated with glutamic acid decarboxylase antibodies. J Autoimmun 101:35\u201347. https:\/\/doi.org\/10.1016\/j.jaut.2019.04.007","journal-title":"J Autoimmun"},{"issue":"1","key":"6841_CR145","doi-asserted-by":"publisher","first-page":"e000076","DOI":"10.1136\/bmjdrc-2014-000076","volume":"3","author":"EP S\u00f8rgjerd","year":"2015","unstructured":"S\u00f8rgjerd EP, Thorsby PM, Torjesen PA, Skorpen F, Kval\u00f8y K, Grill V (2015) Presence of anti-GAD in a non-diabetic population of adults; time dynamics and clinical influence: results from the HUNT study. BMJ Open Diabetes Res Care 3(1):e000076. https:\/\/doi.org\/10.1136\/bmjdrc-2014-000076","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"6841_CR146","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00125-009-1438-0","volume":"52","author":"P Achenbach","year":"2009","unstructured":"Achenbach P, Lampasona V, Landherr U et al (2009) Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 52(9):1881\u20131888. https:\/\/doi.org\/10.1007\/s00125-009-1438-0","journal-title":"Diabetologia"},{"issue":"8","key":"6841_CR147","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00125-025-06434-2","volume":"68","author":"LA Ferrat","year":"2025","unstructured":"Ferrat LA, Templeman EL, Steck AK et al (2025) Type 1 diabetes prediction in autoantibody-positive individuals: performance, time and money matter. Diabetologia 68(8):1709\u20131720. https:\/\/doi.org\/10.1007\/s00125-025-06434-2","journal-title":"Diabetologia"},{"issue":"11","key":"6841_CR148","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1089\/dia.2023.0276","volume":"25","author":"KMW Simmons","year":"2023","unstructured":"Simmons KMW, Frohnert BI, O\u2019Donnell HK et al (2023) Historical insights and current perspectives on the diagnosis and management of presymptomatic type 1 diabetes. Diabetes Technol Ther 25(11):790\u2013799. https:\/\/doi.org\/10.1089\/dia.2023.0276","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"6841_CR149","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2337\/diacare.27.6.1399","volume":"27","author":"JM Barker","year":"2004","unstructured":"Barker JM, Goehrig SH, Barriga K et al (2004) Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 27(6):1399\u20131404. https:\/\/doi.org\/10.2337\/diacare.27.6.1399","journal-title":"Diabetes Care"},{"issue":"9","key":"6841_CR150","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2337\/dc17-0166","volume":"40","author":"SB Johnson","year":"2017","unstructured":"Johnson SB, Lynch KF, Roth R, Schatz D, TEDDY Study Group (2017) My child is islet autoantibody positive: impact on parental anxiety. Diabetes Care 40(9):1167\u20131172. https:\/\/doi.org\/10.2337\/dc17-0166","journal-title":"Diabetes Care"},{"issue":"7","key":"6841_CR151","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1210\/jc.2010-0293","volume":"95","author":"E Bonifacio","year":"2010","unstructured":"Bonifacio E, Yu L, Williams AK et al (2010) Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab 95(7):3360\u20133367. https:\/\/doi.org\/10.1210\/jc.2010-0293","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6841_CR152","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/cei\/uxad139","volume":"215","author":"CL Williams","year":"2023","unstructured":"Williams CL, Marzinotto I, Brigatti C et al (2023) A novel, high-performance, low-volume, rapid luciferase immunoprecipitation system (LIPS) assay to detect autoantibodies to zinc transporter 8. Clin Exp Immunol 215(3):215\u2013224. https:\/\/doi.org\/10.1093\/cei\/uxad139","journal-title":"Clin Exp Immunol"},{"key":"6841_CR153","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/7651_2015_296","volume":"1433","author":"L Yu","year":"2016","unstructured":"Yu L (2016) Islet autoantibody detection by Electrochemiluminescence (ECL) assay. Methods Mol Biol 1433:85\u201391. https:\/\/doi.org\/10.1007\/7651_2015_296","journal-title":"Methods Mol Biol"},{"key":"6841_CR154","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cca.2016.08.013","volume":"462","author":"M Amoroso","year":"2016","unstructured":"Amoroso M, Achenbach P, Powell M et al (2016) 3 Screen islet cell autoantibody ELISA: a sensitive and specific ELISA for the combined measurement of autoantibodies to GAD65, to IA-2 and to ZnT8. Clin Chim Acta 462:60\u201364. https:\/\/doi.org\/10.1016\/j.cca.2016.08.013","journal-title":"Clin Chim Acta"},{"issue":"1","key":"6841_CR155","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/dom.16002","volume":"27","author":"B Dufrusine","year":"2025","unstructured":"Dufrusine B, Natale L, Sallese M et al (2025) Development and validation of a novel method for evaluation of multiple islet autoantibodies in dried blood spot using dissociation-enhanced lanthanide fluorescent immunoassays technology, specific and suitable for paediatric screening programmes. Diabetes Obes Metab 27(1):414\u2013418. https:\/\/doi.org\/10.1111\/dom.16002","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"6841_CR156","doi-asserted-by":"publisher","first-page":"e0242049","DOI":"10.1371\/journal.pone.0242049","volume":"15","author":"F de Jesus Cortez","year":"2020","unstructured":"de Jesus Cortez F, Gebhart D, Robinson PV et al (2020) Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR. PLoS ONE 15(11):e0242049. https:\/\/doi.org\/10.1371\/journal.pone.0242049","journal-title":"PLoS ONE"},{"key":"6841_CR157","doi-asserted-by":"publisher","unstructured":"Choi R, Lee S, Lee E, Kim H, Lee S (2022) Method performance verification of anti-GAD65 and anti-insulin antibody assays. Clin Lab 68(7). https:\/\/doi.org\/10.7754\/clin.lab.2021.210923","DOI":"10.7754\/clin.lab.2021.210923"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06841-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06841-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06841-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:53:57Z","timestamp":1793109237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06841-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":157,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["6841"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06841-z","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors wish to thank Breakthrough T1D for inviting and organising the author working group and for providing funding to host the first consensus workshop, held on 20 November 2024 in Paris, France. Attendance at this workshop was also possible for virtual participants via a videoconference link. Breakthrough T1D also provided funding to R. Brines, Bite Medical Consulting, who supported the author group by collating and compiling author revisions during the manuscript drafting process and assisted in facilitating and documenting outcomes from the working group deliberations. The authors thank C. Mathieu (KU Leuven, Leuven, Belgium), R. Besser (University of Oxford, Oxford, UK) and E. Bosi (San Raffaele, Milan, Italy) for their valuable contributions to improving the manuscript.","order":1,"name":"Ethics","label":"Acknowledgements","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"No new data were created or analysed in this article. All data supporting the findings of this consensus report are available within the article or from the references cited within the article.","order":2,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This consensus opinion was supported by Breakthrough T1D.","order":3,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"A-GZ has served as a board member or advisory panel member for Sanofi and Lilly. MJR has served as a board member or advisory panel member for Sanofi and has acted as a consultant for Lilly. PA has served as a board member or advisory panel member for Sanofi and has received speaker\u2019s honorarium from Sanofi. EB has received speaker\u2019s honorarium from Sanofi. LAD has worked as a consultant for Vertex and Tandem and has received research support (to their institution) from Sanofi and Mannkind. LAD declares stocks or shares in Lilly. SD has served as a board member or advisory panel member for Sanofi and received speaker\u2019s honorarium from Sanofi. AA-O\u2019s organisation receives speaker\u2019s honorarium and unrestricted grant support from Sanofi. HEL has received speaker\u2019s honorarium from Sanofi and Novo Nordisk. LMJ has served as a board member or advisory panel member for Insulet and Sanofi. RM has served as a board member or advisory panel member for Sanofi, received research support and speaker\u2019s honorarium from Sanofi, and has acted as a consultant for Sanofi. Financial compensation for these activities has been received by his institutions. PN has served as a board member or advisory panel member for Sanofi, has acted as a consultant for Sanofi, and has received speaker\u2019s honorarium from Sanofi. TO has received speaker\u2019s honorarium and research support from Sanofi. SSR has acted as a consultant for Westat and has received speaker\u2019s honorarium and served on advisory panels for Sanofi. AS has received speaker\u2019s honorarium and has served as a board member or advisory panel member. RV has served as a board member or advisory panel member for Sanofi and has received research support from Sanofi. JMW serves on advisory boards for Sanofi, SAB Biosciences and Mozart Therapeutics. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The outline for the manuscript was drafted by AGZ, MR, SD and AA-O. The first draft of the manuscript was created by AGZ and MR following the initial one-day workshop in Paris, based on the presentations at the workshop, as a discussion catalyst for the working group discussions. Subsequently, all authors contributed edits to the interpretation of key concepts, information and supporting research, particularly from within their working group perspective, over 15 serial drafts of the final manuscript. These edits were collated by a medical writer who also maintained version control across the serial drafts. AGZ and MR are the guarantors of this work and take responsibility for the integrity of the analysis. All authors have reviewed, helped to revise and have approved the final version of this manuscript.","order":5,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}